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By connecting the cytoplasms of adjacent cells, gap junctions (GJs)
allow the transfer of molecules up to approximately 1 kDa including
ions, metabolites and second messengers. Gap junction intercellular
communication (GJIC) is important in different physiological process-
es including cell differentiation, proliferation, electrical transmission
and inﬂammation (reviewed in [1,2]). The main components of GJs
are the transmembrane proteins connexins (Cxs), six of which can
oligomerise to form a homomeric (composed of the same Cx type)
or heteromeric (composed of more than one Cx type) hemichannel.
A hemichannel can dock with a hemichannel on a neighbouring cell
1953C.A. Scott et al. / Biochimica et Biophysica Acta 1818 (2012) 1952–1961to form a homotypic GJ channel, consisting of the same two hemi-
channel types, or a heterotypic GJ channel, comprising different
hemichannel types. 21 Cx types are found in humans and 20 in
mice with most tissue types expressing one or more Cx proteins. A
range of diseases are attributable to Cx gene mutations including syn-
dromic disease (in which multiple tissue types are affected), skin dis-
ease, non-syndromic hearing loss (NSHL) (hearing loss only),
cataracts and neurological disorders. Here, we focus on what is
known about the role of Cxs in epidermal barrier homeostasis,
wound healing and the association of Cx gene mutations with skin
disease.
2. Connexin localisation in the epidermis
The epidermis of skin is made up of the basal (deepest) layer (BL),
spinous layer (SL), granular layer (GL) and the uppermost stratum
corneum (SC). Keratinocyte (skin) cells undergo a differentiation pro-
gram characterised by the expression of different markers as they mi-
grate upwards from the mitotically active BL to ultimately form the SC
composed of dead anucleated corneocytes.
Cxs have an important role in epidermal physiology, indicated by
the expression of multiple Cx types in the skin and epidermal ap-
pendages, and the link between Cx gene mutations and disease in-
volving the skin. GJs are expressed throughout the epidermis, with
the exception of the SC [3,4], and Cxs are expressed in each epidermal
layer with some overlap in expression of the different Cx types, indi-
cating a purpose for Cxs in coordinating keratinocyte differentiation
[5,6].
Cx26, Cx30, Cx30.3, Cx31.1, Cx37 and Cx43 are expressed in both
human [7,8] and rodent epidermis [4,9,10]. In human interfollicular
skin, Cx30, Cx30.3, Cx31 and Cx45 are expressed in the GL and low
levels of Cx26 in the BL and GL of palmoplantar skin [6,8,11]. Cx43
is mainly expressed in the suprabasal layers, the highest expression
of which is in the GL [8,12]. In adult rodents, Cx43 is predominantly
expressed in the BL and Cx26, Cx30, Cx31 and Cx31.1 in the supraba-
sal layers [4,13–15].
3. Differential connexin localisation in the skin after wounding
Wound healing involves a complex sequence of events including
inﬂammation, tissue formation and remodelling. Keratinocytes at
the wound margins proliferate and migrate into the wound where
differentiation occurs to repair the breached epidermal barrier
(reviewed in [16]). Expression patterns of Cx proteins during
wound closure in rodent skin and in ex vivo wound healing models
have shown differential Cx expression in response to injury, indica-
tive of key functions for Cxs in wound remodelling [14,17,18].
The differential expression of certain Cx types during keratinocyte
differentiation and the wound healing process could permit critical
alterations in GJIC which allow these physiological processes to
occur. However, increasing numbers of studies are revealing Cx inter-
acting partners and cellular functions for Cxs which are irrespective of
their GJ function (reviewed in [19–21]). For example, Cx43 has been
found to interact with structural, signalling and membrane proteins
including zona occludens proteins, members of which are constitu-
ents of tight junctions and adherens junctions, and catenins, which
are components of adherens junctions (reviewed in [20]). Thus, po-
tentially Cxs may mediate effects on epidermal biology by non-GJ
mechanisms via Cx partner proteins.
The majority of studies investigating the differential expression of
Cxs in wound healing have focused on Cx26, Cx30 and Cx43
(Sections 3.1 and 3.2). Cx31.1 expression initially decreased at the
wound site in rodents [14,17]. Levels returned to normal after 6 days
in rats [17]. However an increase in Cx31.1 expression was noted after
7 days in mice before returning to normal at 12 days, indicative of a
role for Cx31.1 in terminal differentiation [14]. Cx31was downregulatedin the suprabasal layer after injury in mice, with levels increasing after
day 3 [15]. However expression in the BL increased up to day 3 before
returning to low levels characteristic of uninjured skin [15].
3.1. Connexin 26 and Connexin 30
Initially, the expression of Cxs types studied was low at the wound
site and proximal areas after injury, followed by an upregulation of
some Cx types at different time points [14,17,18]. Cx26 and Cx30
were upregulated in response to wounding, although the exact loca-
tion at which this occurs differs between studies, and between spe-
cies examined [14,17,18]. In rats, Cx26 expression increased behind,
but not at, the wound edge between 6 h to 6 days after gouging
[17]. A similar expression pattern for Cx26 and Cx30 was observed
in human ex vivo wound healing models [18]. Tape-stripping of
human skin led to increased Cx26 expression throughout the epider-
mis [6]. In mice, Cx26 and Cx30 were upregulated behind the edge of,
and in, the leading edge of the wound 1–4 days after injury [14].
The reason for Cx26 and Cx30 upregulation during the initial
wound healing response is unclear. Mutations in both GJB2 and
GJB6, which encode Cx26 and Cx30 respectively, are linked to syndro-
mic disorders characterised by epidermal thickening (Sections 5.1
and 5.2). GJB2 has also been identiﬁed as a psoriasis susceptibility
locus in the Chinese population [22]. The persistent expression of
Cx26 in murine epidermis resulted in hyperproliferation and hin-
dered wound healing [23], and in chronic leg ulcers Cx26 and Cx30
were present at, and in close proximity to, the wound margins [18].
Cx26 was upregulated in human hyperproliferative psoriatic lesions
compared to non-lesional skin [6,24], however Cx26 was also found
to be highly expressed in normal buccal and vaginal epithelium, sug-
gesting that Cx26 has a role in normal keratinocyte differentiation [6].
Collectively, these studies indicate that Cx26 and Cx30 may con-
trol wound healing by regulating keratinocyte proliferation, differen-
tiation and/or migration, but that their abnormal expression in the
epidermis can be associated with hyperproliferative disease and
may be detrimental to wound closure [14,17,18].
Perhaps surprisingly, Cx26 expression is not essential in skin, pos-
sibly because of compensatory mechanisms by other Cxs in the epi-
dermis. Patients homozygous for some of the most frequent NSHL
GJB2 mutations such as c.35delG and c.235delC, which cannot form
functional GJs [25,26], have NSHL but not skin disease. Interestingly,
an increased epidermal thickness, but not skin pathology, is associat-
ed with being a carrier of c.35delG or of another NSHL Cx26 mutant,
p.R143W, and it has been suggested that they may confer a heterozy-
gote advantage to carriers [27–30] (reviewed in [31]).
3.2. Connexin 43
After wounding, Cx43 expression decreased at the wound site and
surrounding areas in the epidermis of rats, mice and humans
[14,17,32] and Cx43 remained low throughout the entire wound
healing process in humans [18]. However, Cx43 was expressed at
the margins of chronic non-healing wounds in humans [18] and in
the wound edges of diabetic mice, which are slow to heal [33]. This
demonstrates that Cx43 downregulation appears to be necessary for
efﬁcient wound re-epithelialisation [18,33].
A reduction in Cx43 hemichannel and/or GJ function by Cx43
knockdown or Cx43 mimetic peptides, has been shown to increase
wound healing time and reduce inﬂammation, which may warrant
their use in the future as therapeutics [15,34–38]. Transient Cx43
knockdown in areas of epidermal wounding or burn lesions in mice
led to increased keratinocyte proliferation, increased keratinocyte
and ﬁbroblast migration, decreased inﬂammation, swifter wound clo-
sure and reduced scarring [34–36].
The mimetic peptides Gap26 and Gap26M, which interact with
different Cx types, and Gap27, which targets Cx43, were found to
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creased keratinocyte and ﬁbroblast migration into the wound of 3D
mouse organotypic cultures [39]. It also increased the migration and
proliferation of normal human keratinocytes and ﬁbroblasts and ac-
celerated wound closure in 3D human organotypic cultures and ex
vivowound healing models [38]. However, keratinocytes from diabet-
ic patients showed decreased sensitivity to Gap27 compared to con-
trol, illustrating a potentially variable response of cells of different
origin to the peptides [38].
Mice expressing the truncating Cx43 mutant p.K258X displayed
aberrant barrier formation [40] and ﬁbroblasts isolated from patients
with Oculodentodigital dysplasia (ODDD) Cx43 mutants, which dis-
play reduced GJIC, showed impaired migration and proliferation
[41]. These investigations indicate that transient inhibition of Cx43
expression or GJ function promotes wound healing, but that chronic
loss of Cx43 function could have a detrimental effect on epidermal
barrier homeostasis and wound healing.4. Mechanism of connexin mutations in disease
How Cx disease mutants cause pathogenesis in vivo is unclear for
the majority of mutants, although functional investigations have
given insights into potential disease-associated mechanisms (Fig. 1).
A Cx mutant could be unable to form functional GJ channels, thus
ablating its normal physiological role in a tissue it is expressed in. For
example, insertion/deletion NSHL Cx26 mutants such as c.35delG re-
sult in a truncated Cx26 protein that cannot form functional GJs [25].
Loss of normal Cx26 function may impair K+ recycling in the inner
ear [42,43] and cause cell death in the cochlea, leading to deafness
[44,45]. However, the loss of functional Cx26 GJs only in the epider-
mis is not the sole cause of skin disease, as patients homozygous for
loss of function deafness mutations do not exhibit skin pathology.
A mutant may mistrafﬁc, and instead of reaching the cell surface
membrane accumulates in organelles or leads to endoplasmic reticu-
lum (ER) stress. For example, X-linked Charcot–Marie–Tooth (CMTX)
disease Cx32 mutants accumulate in the ER and Golgi apparatus
[46–49] and ER stress is associated with the overexpression of ery-
throkeratoderma variabilis (EKV) Cx31 mutants [50].
The exertion of a dominant negative effect by a Cx mutant on the
functioning of wild-type Cx protein and/or on other Cx types could
lead to disease. Speciﬁc Cx types can form heteromeric hemichannels
and heterotypic GJs with other selected Cx types, such as Cx31 with
Cx26, Cx30 and Cx32 [11,51] thus a Cx mutant may also affect other
Cxs it interacts with. An example of this is the palmoplantar kerato-
derma (PPK) and deafness mutant p.del42E, which was shown to
have a dominant negative effect on Cx26, Cx37 and Cx43 [52]. As
Cxs may interact with partner proteins (reviewed in [20]), it is possi-
ble that a mutant could also have a dominant negative effect on a Cx
binding protein.Fig. 1. Potential disease mechanisms associated with Cx mutations linked to skin disease. EKV
keratoderma; VS, Vohwinkel syndrome.A Cx mutant may be incorporated into hemichannels, but at the
plasma membrane they cause deregulated exchange of molecules
with the extracellular environment. In vitro studies with certain syn-
dromic Cx26 and Cx30 mutants have indicated that they form ‘leaky’
hemichannels at the cell surface [53–56]. If aberrant hemichannels
were expressed in the epidermis, they could lead to deregulated re-
lease of molecules such as ATP, leading to skin disease pathology [53].
5. Connexins and skin disease
The important physiological role of Cxs in tissue is demonstrated
by the range of different Cx types often expressed in a single tissue,
and the link between Cx gene mutations and disease. The ﬁrst report
of a link between mutations in a Cx gene and disease was in 1993
when different mutations in GJB1 (Cx32) were identiﬁed in patients
with CMTX disease [57]. Mutations in GJB2 (Cx26), GJB3 (Cx31),
GJB4 (Cx30.3) and GJB6 (Cx30) are linked to syndromic disease, skin
disease only and NSHL, and in GJA1 (Cx43) to ODDD with or without
PPK (Table 1).
5.1. Syndromic skin disease caused by Connexin 26 mutations
Speciﬁc dominant missense and deletion mutations in GJB2 (Cx26)
the majority of which affect amino acids in the N-terminus (NT) or the
ﬁrst extracellular loop (EL1), are associated with syndromic skin dis-
ease (Table 2). A generalised characteristic of syndromic skin diseases
linked to Cx26 mutations is PPK and deafness. Cx26 mutations are im-
plicated in causing PPK with deafness only, the ‘classical’ form of
Vohwinkel syndrome (VS), keratitis–ichthyosis–deafness (KID) syn-
drome, Bart–Pumphrey syndrome (BPS) and hystrix-like ichthyosis–
deafness (HID) syndrome. Certain Cx26 mutations cause different dis-
eases indicating clinical heterogeneity, for example p.D50N is linked
to KID syndrome [58–62] and HID syndrome [63]. Cx26 mutations
are also associated with NSHL [64], a full list of dominant and recessive
mutations can be found on The Connexin–deafness homepage [65].
BPS is characterised by knuckle pads on the metacarpophalangeal
and interphalangeal joints of the hand, leukonychia (whitening of the
nails) and sensorineural hearing loss [66]. Two Cx26 mutations,
p.N54K [67] and p.G59S [68], have been found to be associated with
BPS. Immunohistochemical staining on lesional skin from a BPS pa-
tient with p.N54K showed that the trafﬁcking of Cx26, Cx30 and
Cx43 did not appear to be disrupted but that Cx30 was upregulated,
possibly to functionally compensate for expression of p.N54K [67].
KID syndrome patients present with mild to severe sensorineural
loss, keratitis which can lead to blindness, loss of eyelashes and eye-
brows and increased susceptibility to infections and squamous cell
carcinoma. Hyperkeratosis, PPK and the development of localised
red/brown hyperkeratotic lesions can occur in patients [69,70]
(Fig. 2). The mutation p.G45E was found to be associated with severe
disease, causing fatality in the ﬁrst year of life [61,71]. HID syndrome, erythrokeratoderma variabilis; KID, keratitis–ichthyosis–deafness; PPK, palmoplantar
Table 1
Skin diseases associated with connexin gene mutations.
Cx gene/protein Chromosomal band
(hg19 assembly)
Disease Inheritance OMIM
GJB2 (Cx26) 13q12.11 BPS D 121011
Deafness and PPK D
HID syndrome D
KID syndrome D
VS D
GJB3 (Cx31) 1p34.3 EKV D/R 603324
GJB4 (Cx30.3) 1p34.3 EKV D 605425
GJB6 (Cx30) 13q12.11 HED D 604418
GJA1 (Cx43) 6q22.31 ODDD with PPK D 121014
BPS: Bart–Pumphrey syndrome, EKV: erythrokeratoderma variabilis, HED: hidrotic
ectodermal dysplasia, HID: hystrix-like ichthyosis–deafness, KID: keratitis–ichthyosis–
deafness, ODDD: oculodentodigital dysplasia, PPK: palmoplantar keratoderma, VS:
Vohwinkel syndrome.
Fig. 2. Keratitis–ichthyosis–deafness (KID) syndrome. Rugose hyperkeratosis on the
lower face (A), verrucous hyperkeratosis on the ear lobe (B) and extensive hyperkera-
tosis on the distal limbs and plantar surface of the feet (C) in a patient with the Cx26
mutation p.D50N.
1955C.A. Scott et al. / Biochimica et Biophysica Acta 1818 (2012) 1952–1961shows clinical overlap with KID syndrome, however HID syndrome is
characterised by the presence of ‘spiky’ hyperkeratosis with a cobble-
stone-like presentation over the body [63]. KID syndrome mutations
are found in the NT or EL1 of Cx26. The NT and NT/EL1 boundaries
of Cxs have been hypothesised to have a role in voltage sensing in
GJs [72]. X-ray crystallography of Cx26 has shown that the NT and
NT/EL1 boundaries are located in regions which may be important
in determining size restriction and pore selectivity [73], thus muta-
tions in these regions could inﬂuence GJ properties and thus cause
disease.
Characteristics of the ‘classical’ form of VS, or VS linked to Cx26
mutations, include sensorineural deafness, constriction of the digits
(pseudoainhum) which may lead to autoamputation and starﬁsh-
like keratosis [74,75]. Hair abnormalities are not present. Both
‘classical’ VS and a distinct disorder, VS with ichthyosis, are charac-
terised by pseudoainhum. VS with ichthyosis differs from ‘classical’
VS in that the disorder is linked to one base pair insertion mutationsTable 2
Mutations in GJB2 (Cx26) associated with syndromic disease.
Disease OMIM Mutation Disease Reference
BPS 149200 c.162CNA/p.N54K EL1 [67]
c.175GNA/p.G59S EL1 [68]
Clouston-like syndrome
and deafness
– c.42CNG/p.N14K NT [130]
HID syndrome 602540 c.148GNA/p.D50N EL1 [63]
KID syndrome 148210 c.34GNC/p.G12R NT [58]
c.40ANT/p.N14Y NT [131]
c.50CNT/p.S17F NT [58]
c.119CNT/p.A40V EL1 [132]
c.134GNA/p.G45E EL1 [61]
c.148GNA/p.D50N EL1 [58–62]
c.148GNT/p.D50Y EL1 [60]
Mucocutaneous
abnormalities and
deafness
– c.424TNC/p.F142L TM3 [133]
PPK with deafness 148350 c.125delAGG/p.del42E EL1/TM1 [52]
c.160ANC/p.N54H EL1 [134]
c.175GNC/p.G59R EL1 [135]
c.176GNC/p.G59A EL1 [136]
c.196GNC/p.D66H EL1 [137]
c.219ANG/p.H73R EL1 [138]
c.224GNA/p.R75Q EL1 [139]
c.223CNT/p.R75W EL1 [140]
c.389GNT/p.G130V CL [141]
c.548CNT/p.S183F EL2 [81]
VS 124500 c.175GNA/p.G59S EL1 [62]
c.193TNC/p.Y65H EL1 [82]
c.196GNC/p.D66H EL1 [74]
c.389GNT/p.G130V CL [75]
BPS: Bart–Pumphrey syndrome, CL: cytoplasmic loop, EL: extracellular loop, HID:
hystrix-like ichthyosis–deafness, KID: keratitis–ichthyosis–deafness, NT: N-terminus,
PPK: palmoplantar keratoderma, TM: transmembrane, VS: Vohwinkel syndrome.in the loricrin gene, LOR, and thus is considered a loricrin kerato-
derma (OMIM 604117). VS with ichthyosis patients have normal
hearing and generalised ichthyosis [76–78].
It is unclear as to why Cx26 mutations associated with syndromic
disease are dominant, but indicates that the mutant protein acquires
an aberrant function in speciﬁc cell types, leading to disease. Func-
tional investigations have indicated that certain syndromic Cx26 mu-
tants have a dominant negative effect on wild-type Cx26 or on other
Cx types, do not form functional gap junctions and/or form ‘leaky’
hemichannels at the cell surface membrane [52,54–56,79,80]
(Table 3). Speciﬁc PPK and deafness mutants and VS mutants appear
to exert a dominant negative effect, indicated by the retention of
wild-type Cx26 or other Cx types in the cytoplasm of cells, or by
their inhibition of GJIC between GJs [52,79–82]. For example, in trans-
genic mice p.D66H had a dominant negative effect on wild-type Cx26
and Cx30, indicated by their retention in the cytoplasm [79]. When
coexpressed with wild-type Cx26 and Cx30 in Xenopus oocytes [52]
or cell lines [83], p.D66H reduced intercellular coupling, indicating a
dominant negative effect.
Hemichannel activity at the cell surface membrane is believed to
be greatly reduced or absent due to their closure at 1–2 mM of extra-
cellular Ca2+ or higher [84–87] and thus incubation in high Ca2+
should close hemichannels present at the cell surface membrane.
The KID syndrome mutants p.G12R, p.N14K, p.A40V, p.G45E and
p.D50N have been hypothesised to form leaky hemichannels, indicat-
ed by large outward membrane currents from Xenopus oocytes
expressing the mutants, which could be prevented by raising the ex-
tracellular Ca2+ [55,56]. Increased propidium iodide loading of HEK-
293T cells transfected with p.G45E could be prevented by raising
the extracellular Ca2+ levels, leading to the conclusion that this mu-
tant led to aberrant hemichannel formation [54].
However, results of expression studies with KID Cx26 mutants in
Xenopus oocytes, indicating that hemichannels are present, are not al-
ways recapitulated in transfected cells. This might be due to differ-
ences in the processing of the mutants in different model systems.
In addition, there was no evidence of the p.S17F mutant forming
hemichannels even in Xenopus oocytes, indicating a different
Table 3
Functional investigations performed with Connexin mutants associated with skin disease.
Cx Assay Mutation Result/reference
Cx26 Expression in Xenopus oocytes, DVC p.S17F Reduced membrane currents, indicating absence of normal hemichannel activity [56]
p.del42E, p.D66H DNE on Cx26, Cx43 (both mutants) and on Cx37 (p.del42E) only [52]
p.G12R, p.N14K, p.A40V,
p.G45E, p.D50N
Increased outward currents and oocyte death [55,56,132], rescued by 2–4 mM [Ca2+]E,
indicating abnormal hemichannels [55,56]
p.R75W DNE on wild-type Cx26 [140]
Expression in HeLa or HEK-293 cells p.N14K Cell death, retention in the ER [89]
p.G45E Cell death, rescued by 3.2 mM [Ca2+]E. Reduced PI loading at 3.2 mM [Ca2+]E, indicating
abnormal hemichannels [54]
p.D50N Cell death, not rescued by raising 3.6 mM Ca2+E [88]
p.G59A, p.D66H, p.R75W DNE on wild-type Cx26 [80,83], Cx30 (p.R75W, p.G59A) [83], Cx32 (p.G59A) and Cx43
(p.D66H) [80]
p.H73R DNE on wild-type Cx26 [138]
Expression in the suprabasal layer of
mouse epidermis
p.D66H Hyperkeratosis, increased TUNEL staining. DNE on Cx26 and Cx30 [79]
Conditional mouse mutant p.S17F Hyperplasia, hyperkeratosis, hearing impairment, no corneal defects [142]
Cx30 Expression in Xenopus oocytes, DVC p.G11R, p.A88V Increased outward currents and oocyte death, rescued by 2.9 mM [Ca2+]E [53]
Expression in HeLa cells p.G11R, p.A88V Cell death and increased ATP release, which could be reduced by α-GA [53]
Cx31 Expression in HeLa cells/immortalised
keratinocyte cells
p.G12D, p.R42P, p.C86S Cell death [50,96,114], not rescued by 3.6 mM [Ca2+]E, upregulation of UPR markers [50].
Reduced cell coupling (p.G12D) [116]
Expression in HeLa cells p.G12R Cell death, increased intercellular dye transfer [115]
α-GA: α-glycyrrhetinic acid, [Ca2+]E: extracellular Ca2+, DNE: dominant negative effect, DVC: dual voltage clamp, PI: propidium iodide, PPK: palmoplantar keratoderma, UPR: unfolded
protein response.
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the cell death phenotype caused by overexpression of the mutant
p.D50N in Xenopus oocytes [56] but not in transfected HEK-293T
cells in vitro [88]. Decreased cell viability was observed for HeLa
cells transfected with p.N14K, however the mutant had a cytoplasmic
localisation and appeared to be retained in the ER, indicating that de-
fective protein trafﬁcking could lead to disease [89].
5.2. Hidrotic ectodermal dysplasia (HED) caused by Connexin 30 mutations
Speciﬁc dominant missense mutations in GJB6 (Cx30) are associat-
ed with hidrotic ectodermal dysplasia (HED), also known as Clouston
syndrome. These include p.G11R and p.A88V [90], which have also
been discovered in cases of atypical pachyonychia congenita [91], and
p.V37E [92]. A patient with KID syndrome with atrichia (absence
of hair) was found to harbour the Cx30 mutation p.V37E, possibly
because of a similar functional effect of this mutant compared to KID
syndrome Cx26 mutants [93]. There is some overlap in the expression
of Cx26 and Cx30 in palm skin [8] and the cochlea [94] and the two
have been shown to interact in vitro [11]. This, and the phenotypic
similarities between diseases linked to Cx26 and Cx30 mutants,
indicate that the two proteins have similar functional roles in vivo.
HED patients display nail hypoplasia, PPK, skin hyperpigmenta-
tion and hair defects which can cause total alopecia. Overexpression
of p.G11R and p.A88V in Xenopus oocytes showed that although GJs
were formed, their conductance properties were altered [53]. Large
outward membrane currents were discovered and oocyte death oc-
curred, which could be rescued by raising the extracellular Ca2+
levels, indicating the presence of aberrant hemichannels [53].
5.3. Erythrokeratoderma variabilis (EKV) caused by Connexin 30.3 and
Connexin 31 mutations
The main feature of erythrokeratoderma is the presence of loca-
lised demarcated hyperkeratotic (thickened) skin lesions in patients.
The two major erythrokeratoderma types are EKV and progressive
symmetric erythrokeratoderma (PSEK), which display phenotypic
and genetic heterogeneity.
EKV, also called Mendes da Costa syndrome or erythrokeratoder-
mia variabilis, normally presents at birth or early in infancy. In addi-
tion to ﬁxed red/brown hyperkeratotic lesions which are frequently
present on the trunk, limbs and buttocks, patients display migratoryerythematous patches which can change in shape and location over
time (Fig. 3). PPK may also be present [95]. Symptoms may become
aggravated by stress and changes in temperature [96], indicating
that environmental factors may also inﬂuence the skin phenotype.
PSEK, also called Gottron syndrome or erythrokeratodermia progres-
sive symmetrica, has clinical overlap with EKV, differing by the ab-
sence of transient erythema. The clinical similarities between EKV
and PSEK may make it difﬁcult to distinguish them [97] and it has
been suggested that the two are the same disorder with different pre-
sentations [98]. Hearing, nails and development are normal in both
conditions.
Mutations in GJB3 (Cx31) and GJB4 (Cx30.3) are associated with
dominant and recessive EKV (Table 4). EKV has also been described
as a component of MEDNIK (Mental retardation, Enteropathy, Deaf-
ness, Neuropathy, Ichthyosis and Keratodermia) syndrome found in
three families with a common ancestor and linked to a mutation in
the AP1S1 gene, which encodes the σ1A subunit of the AP-1 complex
[99]. This indicates that AP1S1 could be involved in the trafﬁcking of
Cx30.3/Cx31.
The Cx30.3 mutation p.G12D is associated with EKV [100] and PSEK
[101], and the Cx30.3mutation p.F137L has been implicated in EKVwith
[102] or without [103] erythema gyratum repens. A one base pair dom-
inant insertion mutation in LORwas associated with a PSEK-like pheno-
type with pseudoainhum in one family [104]. However, the features
appear to be consistent with loricrin keratoderma rather than true
PSEK [98,105]. Genetic heterogeneity for EKV and PSEK is indicated as
not all EKV patients have mutations in either gene [106–110] and no
mutations were found in LOR, GJB3 or GJB4 in PSEK patients [111,112].
A mouse model of EKV expressing the Cx31 mutant p.F137L has
been developed [113]. However, mice homozygous for the mutant
died during embryonic development and only 5% of murine skin
was affected, indicated by hyperproliferation, in mice heterozygous
for the mutant [113].
Overexpression of EKV Cx31 mutants in vitro has demonstrated
that the mutants have a primarily cytoplasmic localisation/display re-
duced GJ plaque formation and are associated with a cell death phe-
notype in certain cell types, including keratinocytes [50,96,114,115].
There are some discrepancies in results obtained between studies
for the EKV Cx31 mutants p.G12R and p.G12D, possibly due to differ-
ences between cell culture conditions and constructs.
p.G12D and p.G12R were reported to cause increased cell death in
HeLa cells and immortalised keratinocyte cell lines and display
Fig. 3. Erythrokeratoderma variabilis (EKV). Red/brown hyperkeratotic lesions on the trunk and limbs (A–C). Patient harbours the Cx30.3 mutation p.R98L, of unknown clinical sig-
niﬁcance (A). Patient has the Cx30.3 mutation p.M190L (B and C).
1957C.A. Scott et al. / Biochimica et Biophysica Acta 1818 (2012) 1952–1961defective trafﬁcking to the plasma membrane [50,96,114]. However,
in two other studies involving the expression of p.G12D [116] or
p.G12R [115] in HeLa cells, trafﬁcking defects were not evident, al-
though p.G12R reduced cell viability.
Unlike for other syndromic Cx mutants, high levels of extracellular
Ca2+ did not rescue the cell death phenotype of cells expressing EKV
Cx31 mutants, indicating that ‘leaky’ hemichannels are not responsi-
ble for the cell death phenotype [50]. It is unknown if this cell death
phenotype is recapitulated in patient skin. In EKV patient skin, the
Cx31 mutant p.R42P had a perinuclear localisation [96] but no obvi-
ous structural abnormalities were present [117].
ER stress is linked to different disorders (reviewed in [118]). Com-
ponents of the unfolded protein response (UPR), which is initiated in
response to ER stress, are expressed in the skin and speciﬁc UPR pro-
teins were found to be downregulated in squamous cell carcinoma
and psoriasis [119]. ER stress is detected by the ER membrane pro-
teins ATF6, IRE1α/β and PERK, resulting in UPR activation which
leads to attenuation of protein production and an upregulation of
ER chaperones such as BiP/GRP78 (reviewed in [120]). For example,
ATF6 is cleaved upon activation, translocating to the nucleus and act-
ing as a transcription factor to upregulate the expression of other UPR
proteins [121].
An upregulation of UPR components and proteasomal markers
was associated with the in vitro overexpression of EKV Cx31 mutants,Table 4
Mutations in GJB4 (Cx30.3) and GJB3 (Cx31) associated with EKV.
Cx Mutation Domain Inheritance Result/reference
Cx30.3 c.35GNA/p.G12D NT D [100]
c.64GNA/p.R22H TM1 D [100]
c.253ANC/p.T85P TM2 D [100]
c.409TNC, c.411CNA/p.F137L TM3 D [100,102]
c.566TNA/p.F189Y TM4 D [100]
c.568ANT/p.M190L TM4 D [108]
Cx31 c.34GNC/p.G12R NT D [143]
c.35GNA/p.G12D NT D [108,143]
c.125GNC/p.R42P EL1 D [105,117]
c.256TNA/p.C86S TM2 D [143]
c.403CNG/p.L135V TM3 D [103]
c.409TNC/p.F137L TM3 D [105]
c.625CNT/p.L209F CT D [108,144]
c.101TNC/p.L34P TM1 R [145]
c.298GNA/p.E100K CL R [146]
CL: cytoplasmic loop, CT: C-terminus, D: dominant, EL: extracellular loop, NT: N-terminus,
R: recessive, TM: transmembrane.but not wild-type, which indicates that ER stress, rather than aberrant
hemichannels, is the main mechanism of cell death for these mutants
[50] (Fig. 4). Expression of an EKV Cx31mutant was also found to lead
to ER stress and p63-dependent apoptosis in zebraﬁsh embryos [122].
A deletion in the 5′ UTR of the proteasome maturation protein
(POMP) gene was found to be associated with Keratosis linearis
with ichthyosis congenita and sclerosing keratoderma syndrome
(KLICK) syndrome [123]. An aberrant distribution of POMP and in-
creased expression of the UPR protein C/EBP homologous protein
(CHOP) was found in patient skin, indicating ER stress is involved in
disease pathology. Future studies involving characterisation of the ex-
pression and localisation of UPR proteins in EKV patient skin, and of
tissue from patients with other Cx gene mutations, will give insights
into the effects that Cx mutants have on UPR pathways in vivo.5.4. Oculodentodigital dysplasia (ODDD) and palmoplantar keratoderma
(PPK)
Speciﬁc GJA1 (Cx43) mutations are associated with ODDD
(OMIM 164200), which is characterised by facial abnormalities, in-
cluding microphthalmia, small teeth and small nose, and syndactyly
type III. Two missense mutations, p.L11P [124] and p.K134E [125],
and two heterozygous deletion mutations leading to Cx43 trunca-
tions in the C-terminus (CT), c.679_680delAT (fs230) [126] and
c.780_781delTG (fs260) [127], have been associated with dominant
ODDD with the additional feature of PPK. However, the fs230 mu-
tant is not always associated with a skin phenotype [128]. 3D rat
organotypic cultures composed of rat epidermal keratinocytes
expressing the fs260 mutant showed decreased Cx26, Cx43 and lor-
icrin levels and a reduction in Cx43 phosphorylation, SC thickness
and resistance to acetone-induced injury, indicating that this mutant
impairs epidermal differentiation and thus contributes to the dis-
ease phenotype [129]. The authors suggested that expression of
the mutant could have a detrimental effect on epidermal junctional
complexes, causing reduced resistance to stress [129]. Cx43 has a
long CT which is known to interact with multiple partner proteins
[20] thus a truncation could inhibit or disrupt interactions which
normally occur with wild-type protein.
Fibroblasts from patients with the Cx43 mutants p.D3N and
p.V216L, which are associated with ODDD only, showed reduced pro-
liferation and migration, and delayed wound healing was observed in
a p.G60S ODDDmutant mouse [41]. These investigations indicate that
Cx43 mutants associated with ODDD could also have subclinical ef-
fects on wound healing in vivo in ODDD patients [41].
Fig. 4. Expression of the Cx31 EKV-causing mutant upregulates components of the unfolded protein response (UPR) pathway. The UPR components BiP/GRP78 (C and D) and ATF6
(G and H) are upregulated in HeLa cells overexpressing the mutant (C86S)Cx31-EGFP (D and H) but not the wild-type construct (WT)Cx31-EGFP (C and G). Furthermore, the ATF6
staining (H) has a more nuclear localisation in cells expressing (C86S)Cx31-EGFP compared to untransfected cells and cells expressing (WT)Cx31-EGFP, indicating that the cleaved
amino-terminal portion has been translocated to the nucleus. The DAPI-stained nuclei are shown in blue.
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The differential expression of Cxs within the epidermis and during
wound healing, as well as the association of Cx mutations with skin
disease, demonstrates a critical role for Cxs in keratinocyte differenti-
ation and wound closure. In vitro functional studies with Cx mutants
and transgenic mice models have given insights into Cx function and
how Cx mutants may cause disease. However, the precise functions of
each Cx type during keratinocyte differentiation and how Cx mutants
cause disease in vivo remain to be deciphered. The use of 3D culture
models, the establishment of patient cell lines and a detailed charac-
terisation of the patient transcriptome, for example, by next genera-
tion sequencing, should provide insights into the roles of Cxs in
normal epidermal function and disease-associated mechanisms.
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